Structure Therapeutics Inc. financial data

Symbol
GPCR on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1984% % -26%
Debt-to-equity 5.8% % 31%
Return On Equity -26% % -59%
Return On Assets -25% % -57%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 182,032,920 shares 6%
Common Stock, Shares, Outstanding 182,033,000 shares 6%
Entity Public Float $1,953,600,000 USD 289%
Common Stock, Value, Issued $18,000 USD 5.9%
Weighted Average Number of Shares Outstanding, Basic 175,469,000 shares 2.2%
Weighted Average Number of Shares Outstanding, Diluted 175,469,000 shares 2.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $190,053,000 USD 99%
General and Administrative Expense $57,557,000 USD 23%
Operating Income (Loss) $247,610,000 USD -74%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $210,204,000 USD -90%
Income Tax Expense (Benefit) $481,000 USD 17%
Net Income (Loss) Attributable to Parent $210,685,000 USD -91%
Earnings Per Share, Basic -1 USD/shares -68%
Earnings Per Share, Diluted -0.37 USD/shares -85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $102,912,000 USD -40%
Cash, Cash Equivalents, and Short-term Investments $799,000,000 USD -13%
Assets, Current $814,022,000 USD -12%
Property, Plant and Equipment, Net $4,675,000 USD 25%
Operating Lease, Right-of-Use Asset $6,863,000 USD 71%
Other Assets, Noncurrent $6,599,000 USD 262%
Assets $832,159,000 USD -11%
Accounts Payable, Current $17,796,000 USD 111%
Employee-related Liabilities, Current $8,551,000 USD 40%
Liabilities, Current $57,527,000 USD 72%
Operating Lease, Liability, Noncurrent $4,288,000 USD 60%
Other Liabilities, Noncurrent $325,000 USD 5.2%
Liabilities $62,140,000 USD 71%
Accumulated Other Comprehensive Income (Loss), Net of Tax $825,000 USD -71%
Retained Earnings (Accumulated Deficit) $503,304,000 USD -72%
Stockholders' Equity Attributable to Parent $770,019,000 USD -14%
Liabilities and Equity $832,159,000 USD -11%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $52,229,000 USD -53%
Net Cash Provided by (Used in) Financing Activities $809,000 USD 15%
Net Cash Provided by (Used in) Investing Activities $34,033,000 USD 2300%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 182,033,000 shares 6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $17,387,000 USD 46%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $102,912,000 USD -40%
Deferred Tax Assets, Valuation Allowance $68,179,000 USD 32%
Deferred Tax Assets, Gross $69,092,000 USD 31%
Operating Lease, Liability $7,090,000 USD 62%
Depreciation $274,000 USD 23%
Payments to Acquire Property, Plant, and Equipment $314,000 USD 94%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $212,699,000 USD -98%
Lessee, Operating Lease, Liability, to be Paid $7,924,000 USD 65%
Property, Plant and Equipment, Gross $5,114,000 USD 32%
Operating Lease, Liability, Current $2,802,000 USD 64%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,721,000 USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,224,000 USD 62%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $834,000 USD 103%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,276,000 USD 234%
Deferred Tax Assets, Operating Loss Carryforwards $26,182,000 USD -10%
Preferred Stock, Shares Authorized 100,000,000 shares 0%
Unrecognized Tax Benefits $7,947,000 USD 806%
Lessee, Operating Lease, Liability, to be Paid, Year Four $938,000 USD
Operating Lease, Payments $600,000 USD 100%
Additional Paid in Capital $1,272,480,000 USD 7.2%
Deferred Tax Assets, Net of Valuation Allowance $913,000 USD -25%
Share-based Payment Arrangement, Expense $26,753,000 USD 78%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%